Actively Recruiting
Comparing Continuous Patch Monitoring and Standard ECGs to Detect Heart Rhythm Problems in Adults Receiving Arsenic Trioxide, Ribociclib, or Capecitabine
Led by Washington University School of Medicine · Updated on 2025-12-30
60
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating a continuous patch monitoring system called BodyGuardian Mini Plus to detect cardiac arrhythmias in patients treated with drugs that may cause heart complications, such as arsenic trioxide, ribociclib, or capecitabine. The study aims to compare this continuous patch system with standard electrocardiograms ECGs to see how well the patch monitors heart activity. Participants receive their usual cancer treatment and will have the BodyGuardian Mini Plus device attached to their upper chest as an adhesive patch. ECG tracings are recorded continuously by the patch and sent to a smartphone and cloud server. During the first 30 days of treatment, participants will have at least five standard ECGs performed to compare with the patch data. Throughout the study, researchers will track and compare measurements from ECGs and the patch monitor, focusing on major arrhythmia events and changes in QT interval over 30 days. Participants will be monitored closely with these devices during this period to assess heart rhythm, with data collected remotely via the patch system. The total participation involves monitoring during the first month of treatment.
CONDITIONS
Brief Title
Continuous Versus Intermittent cARdiac Electrical moNitorinG
Research Team
J
Joshua D Mitchell, M.D., FACC
K
Kaitlin Moore
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
